Dr Jacob Stendall is a consultant clinical oncologist specialising in the treatment of urological cancers, including prostate, bladder, kidney, and testicular cancer. He practices at Charing Cross Hospital, part of Imperial College Healthcare NHS Trust. He was appointed as a consultant in 2021 and is known for delivering advanced cancer therapies with a strong focus on individualised treatment plans.

He has particular expertise in modern radiotherapy techniques such as image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT), and stereotactic ablative radiotherapy (SABR). Dr Stendall also provides systemic anti-cancer treatments including hormone therapy, chemotherapy, and immunotherapy, ensuring patients receive the most appropriate and up-to-date care.

Dr Stendall is actively involved in clinical research and education, contributing to ongoing advancements in cancer care and mentoring medical trainees. His clinical interests include integrating new technologies and evidence-based strategies to improve patient outcomes and quality of life during and after treatment.

He takes a collaborative approach to patient care, working closely with multidisciplinary teams to ensure that each treatment pathway is tailored to the individual’s needs. His practice is centred on compassion, clinical excellence, and patient empowerment.